NIAID (National Institute of Allergy and Infectious Diseases)
Scientific/Medical - Research
Scientific/Medical - Research Group Awards
For outstanding efforts to rapidly discern the safety and efficacy of an anti-malaria monoclonal antibody, CIS43LS, from a Phase 2 clinical trial in Mali.
In recognition of significant contributions to the real-time assessment of emerging SARS-CoV-2 mutations that could impact transmissibility, virulence, and susceptibility to infection or vaccine-induced immunity.